Non-steroidal FXR agonists (i.e. GW4064), which are also being investigated in clinical settings, improved markers of cholestasis as well as reduced hepatic bile acid accumulation in bile duct-ligated and α-naphthyl isothiocyanate-treated rats too36. This evidence concerns the gene NR1H4 and cholestasis.